The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...

A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, "Targeting the multifaceted BRAF in cancer: New directions." In cancer patients, BRAF-targeting precision ...

The U.S. Food and Drug Administration (FDA) has granted plixorafenib a Breakthrough Therapy Designation, signaling ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

European authorities have backed a targeted BRAF/MEK inhibitor combo for radioactive iodine-refractory thyroid cancer and ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...

Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment decisions.

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...

TAS-102 plus bevacizumab in refractory metastatic colorectal cancer: A systematic review and meta-analysis of randomized trials with validation from prospective single-arm studies. This is an ASCO ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...